Senores pharmaceuticals Limited has received a disclosure from promoter group entity Espee Therapeutics LLP regarding the creation of a pledge on 4,00,000 equity shares. The pledge was created on February 13, 2026, and disclosed to the stock exchanges on February 17, 2026, in compliance with SAST Regulations 31(1) and 31(2).

Pledge Details

The pledge transaction involves specific terms and beneficiaries as outlined in the regulatory filing:

Promoter Holdings Structure

The disclosure reveals the comprehensive shareholding pattern of promoters and promoter group entities in Senores Pharmaceuticals Limited:

Key Promoters:

• Swapnil Jatin Shah: 35,53,531 shares (7.72% of total share capital)
• Ashokbhai Vijaysinh Barot: 34,44,869 shares (7.48% of total share capital)

Major Promoter Group Entities:

• Remus Pharmaceuticals Limited: 32,61,744 shares (7.08% of total share capital)
• Renosen Pharmaceuticals Private Limited: 27,18,719 shares (5.90% of total share capital)
• Anar Swapnil Shah: 22,94,500 shares (4.98% of total share capital)
• Aviraj Overseas LLC: 18,95,190 shares (4.12% of total share capital)

Regulatory Compliance

The disclosure was submitted to both BSE Limited (Scrip Code: 544319) and National Stock Exchange of India Limited (Symbol: SENORES) as mandated under SAST Regulations. Swapnil Jatinbhai Shah, serving as Designated Partner of Espee Therapeutics LLP with DIN 05259821, signed the disclosure documents.

Company Information

Espee Therapeutics LLP holds a total of 4,95,000 shares in Senores Pharmaceuticals Limited, representing 1.07% of the total share capital. The pledged amount of 4,00,000 shares constitutes approximately 80.81% of Espee Therapeutics LLP's total holding in the company. The entity is registered with LLPIN AAH-8938 and operates from Ahmedabad.

Senores Pharmaceuticals Limited successfully concluded its Extra-Ordinary General Meeting (EGM) on January 31, 2026, securing shareholder approval for a significant capital raising initiative through convertible equity warrants. Following the successful EGM, the company has now submitted important amendments and clarifications to the original EGM notice under regulatory compliance requirements.

EGM Proceedings and Voting Results

The EGM was conducted at 12:30 P.M. through Video Conferencing (VC) and Other Audio-Visual Means (OAVM), with proceedings concluding at 12:55 P.M. The meeting addressed a single special resolution regarding the issuance of convertible equity warrants to the promoter and promoter group.

Warrant Issuance Approval

Shareholders overwhelmingly approved the special resolution for issuing 11,70,000 convertible equity warrants by way of preferential issue on private placement basis to persons belonging to the promoter and promoter group category. The resolution received strong support across all shareholder categories.

Regulatory Clarifications and Amendments

On February 04, 2026, Senores Pharmaceuticals submitted amendments and clarifications to Item No. 1 of the explanatory statement annexed to the EGM Notice dated January 07, 2026, under Regulation 30 of SEBI LODR Regulations. The company clarified that while the quantum of the proposed issue is less than 5% of the post-issue fully diluted share capital, making Regulation 166A of SEBI ICDR Regulations non-applicable, the company's Articles of Association require obtaining a valuation report from a registered valuer for determining the floor price.

Valuation Methodology

The registered valuer considered three valuation approaches: Asset Approach (Net Asset Value Method), Income Approach (Profit Earning Capacity Value Method), and Market Approach (Market Price Method). Since values calculated under the Profit Earning Capacity Value Method and Net Asset Value Method were less than the Market Price Method value, which also represents the Floor Price as per SEBI ICDR Regulations, the valuer assigned nil weightage to the first two methods and 100% weightage to the market approach.

Regulatory Compliance

Mukesh H. Shah & Co., Company Secretaries, served as the scrutinizer for the voting process, ensuring compliance with Section 108 of the Companies Act, 2013 and Regulation 44 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The clarification document was signed by Vinay Kumar Mishra, Company Secretary and Compliance Officer, and made available on the company's website and stock exchange platforms for stakeholder access.